ID   S4A4_HUMAN              Reviewed;        1079 AA.
AC   Q9Y6R1; C4B714; O15153; Q8NEJ2; Q9H262; Q9NRZ1; Q9UIC0; Q9UIC1; Q9UP50;
DT   20-DEC-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1999, sequence version 1.
DT   07-APR-2021, entry version 167.
DE   RecName: Full=Electrogenic sodium bicarbonate cotransporter 1;
DE            Short=Sodium bicarbonate cotransporter;
DE   AltName: Full=Na(+)/HCO3(-) cotransporter;
DE   AltName: Full=Solute carrier family 4 member 4;
DE   AltName: Full=kNBC1;
GN   Name=SLC4A4; Synonyms=NBC, NBC1, NBCE1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, AND TISSUE SPECIFICITY.
RC   TISSUE=Kidney;
RX   PubMed=9235899; DOI=10.1074/jbc.272.31.19111;
RA   Burnham C.E., Amlal H., Wang Z., Shull G.E., Soleimani M.;
RT   "Cloning and functional expression of a human kidney Na+:HCO3-
RT   cotransporter.";
RL   J. Biol. Chem. 272:19111-19114(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND TISSUE SPECIFICITY.
RC   TISSUE=Pancreas;
RX   PubMed=9651366; DOI=10.1074/jbc.273.28.17689;
RA   Abuladze N., Lee I., Newman D., Hwang J., Boorer K., Pushkin A., Kurtz I.;
RT   "Molecular cloning, chromosomal localization, tissue distribution, and
RT   functional expression of the human pancreatic sodium bicarbonate
RT   cotransporter.";
RL   J. Biol. Chem. 273:17689-17695(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND TISSUE SPECIFICITY.
RC   TISSUE=Heart, Kidney, and Prostate;
RX   PubMed=10069984; DOI=10.1152/ajpcell.1999.276.3.c576;
RA   Choi I., Romero M.F., Khandoudi N., Bril A., Boron W.F.;
RT   "Cloning and characterization of a human electrogenic Na+-HCO-3
RT   cotransporter isoform (hhNBC).";
RL   Am. J. Physiol. 276:C576-C584(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION IN CORNEAL ENDOTHELIAL
RP   CELLS, TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.
RC   TISSUE=Corneal endothelium;
RX   PubMed=12907161; DOI=10.1016/s0014-4835(03)00150-7;
RA   Sun X.C., Bonanno J.A.;
RT   "Identification and cloning of the Na/HCO3- cotransporter (NBC) in human
RT   corneal endothelium.";
RL   Exp. Eye Res. 77:287-295(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4).
RC   TISSUE=Skeletal muscle;
RA   Pushkin A., Abuladze N., Kurtz I.;
RT   "Homo sapiens sodium bicarbonate cotransporter NBC1 splice variant.";
RL   Submitted (JUN-1999) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5).
RA   Yamada H., Nagayoshi A., Kuroda Y., Mizutani A., Ando H., Seki G.,
RA   Mikoshiba K.;
RT   "cDNA cloning and characterization of human sodium bicarbonate
RT   cotransporter, bNBC, a brain type splicing variant of SLC4A4 gene.";
RL   Submitted (NOV-2008) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Kidney;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   REGULATION, MUTAGENESIS OF SER-1026, AND PHOSPHORYLATION AT SER-1026.
RX   PubMed=11744745; DOI=10.1113/jphysiol.2001.012956;
RA   Gross E., Hawkins K., Pushkin A., Sassani P., Dukkipati R., Abuladze N.,
RA   Hopfer U., Kurtz I.;
RT   "Phosphorylation of Ser(982) in the sodium bicarbonate cotransporter kNBC1
RT   shifts the HCO(3)(-):Na(+) stoichiometry from 3:1 to 2:1 in murine proximal
RT   tubule cells.";
RL   J. Physiol. (Lond.) 537:659-665(2001).
RN   [10]
RP   ERRATUM OF PUBMED:11744745.
RA   Gross E., Hawkins K., Pushkin A., Sassani P., Dukkipati R., Abuladze N.,
RA   Hopfer U., Kurtz I.;
RL   J. Physiol. (Lond.) 538:1003-1003(2002).
RN   [11]
RP   TISSUE SPECIFICITY.
RX   PubMed=11743927; DOI=10.1016/s0003-9969(01)00098-x;
RA   Park K., Hurley P.T., Roussa E., Cooper G.J., Smith C.P., Thevenod F.,
RA   Steward M.C., Case R.M.;
RT   "Expression of a sodium bicarbonate cotransporter in human parotid salivary
RT   glands.";
RL   Arch. Oral Biol. 47:1-9(2002).
RN   [12]
RP   REGULATION, MUTAGENESIS OF ASP-1030; ASP-1032 AND ASP-1033, AND INTERACTION
RP   WITH CA2.
RX   PubMed=12411514; DOI=10.1113/jphysiol.2002.029777;
RA   Gross E., Pushkin A., Abuladze N., Fedotoff O., Kurtz I.;
RT   "Regulation of the sodium bicarbonate cotransporter kNBC1 function: role of
RT   Asp(986), Asp(988) and kNBC1-carbonic anhydrase II binding.";
RL   J. Physiol. (Lond.) 544:679-685(2002).
RN   [13]
RP   GLYCOSYLATION.
RX   PubMed=12604466; DOI=10.1152/ajprenal.00131.2002;
RA   Choi I., Hu L., Rojas J.D., Schmitt B.M., Boron W.F.;
RT   "Role of glycosylation in the renal electrogenic Na+-HCO3-cotransporter
RT   (NBCe1).";
RL   Am. J. Physiol. 284:F1199-F1206(2003).
RN   [14]
RP   TISSUE SPECIFICITY.
RX   PubMed=14559244; DOI=10.1016/j.bbrc.2003.09.147;
RA   Yamada H., Yamazaki S., Moriyama N., Hara C., Horita S., Enomoto Y.,
RA   Kudo A., Kawakami H., Tanaka Y., Fujita T., Seki G.;
RT   "Localization of NBC-1 variants in human kidney and renal cell carcinoma.";
RL   Biochem. Biophys. Res. Commun. 310:1213-1218(2003).
RN   [15]
RP   SUBCELLULAR LOCATION, AND TOPOLOGY.
RX   PubMed=12534288; DOI=10.1021/bi026826q;
RA   Tatishchev S., Abuladze N., Pushkin A., Newman D., Liu W., Weeks D.,
RA   Sachs G., Kurtz I.;
RT   "Identification of membrane topography of the electrogenic sodium
RT   bicarbonate cotransporter pNBC1 by in vitro transcription/translation.";
RL   Biochemistry 42:755-765(2003).
RN   [16]
RP   REGULATION, INTERACTION WITH CA2 AND CA4, AND MUTAGENESIS OF GLY-767.
RX   PubMed=14567693; DOI=10.1021/bi0353124;
RA   Alvarez B.V., Loiselle F.B., Supuran C.T., Schwartz G.J., Casey J.R.;
RT   "Direct extracellular interaction between carbonic anhydrase IV and the
RT   human NBC1 sodium/bicarbonate co-transporter.";
RL   Biochemistry 42:12321-12329(2003).
RN   [17]
RP   REGULATION, MUTAGENESIS OF THR-49 AND SER-1026, AND PHOSPHORYLATION AT
RP   THR-49.
RX   PubMed=12730338; DOI=10.1113/jphysiol.2003.042226;
RA   Gross E., Fedotoff O., Pushkin A., Abuladze N., Newman D., Kurtz I.;
RT   "Phosphorylation-induced modulation of pNBC1 function: distinct roles for
RT   the amino- and carboxy-termini.";
RL   J. Physiol. (Lond.) 549:673-682(2003).
RN   [18]
RP   TISSUE SPECIFICITY.
RX   PubMed=15329059; DOI=10.1111/j.1365-201x.2004.01297.x;
RA   Kristensen J.M., Kristensen M., Juel C.;
RT   "Expression of Na+/HCO3- co-transporter proteins (NBCs) in rat and human
RT   skeletal muscle.";
RL   Acta Physiol. Scand. 182:69-76(2004).
RN   [19]
RP   MUTAGENESIS OF PHE-1057, AND SUBCELLULAR LOCATION.
RX   PubMed=15273250; DOI=10.1074/jbc.m405780200;
RA   Li H.C., Worrell R.T., Matthews J.B., Husseinzadeh H., Neumeier L.,
RA   Petrovic S., Conforti L., Soleimani M.;
RT   "Identification of a carboxyl-terminal motif essential for the targeting of
RT   Na+-HCO-3 cotransporter NBC1 to the basolateral membrane.";
RL   J. Biol. Chem. 279:43190-43197(2004).
RN   [20]
RP   INTERACTION WITH CA2, AND MUTAGENESIS OF 1002-LEU--ASN-1004 AND
RP   1030-ASP--ASP-1033.
RX   PubMed=15218065; DOI=10.1113/jphysiol.2004.065110;
RA   Pushkin A., Abuladze N., Gross E., Newman D., Tatishchev S., Lee I.,
RA   Fedotoff O., Bondar G., Azimov R., Ngyuen M., Kurtz I.;
RT   "Molecular mechanism of kNBC1-carbonic anhydrase II interaction in proximal
RT   tubule cells.";
RL   J. Physiol. (Lond.) 559:55-65(2004).
RN   [21]
RP   INTERACTION WITH CA4.
RX   PubMed=15563508; DOI=10.1093/hmg/ddi023;
RA   Yang Z., Alvarez B.V., Chakarova C., Jiang L., Karan G., Frederick J.M.,
RA   Zhao Y., Sauve Y., Li X., Zrenner E., Wissinger B., Den Hollander A.I.,
RA   Katz B., Baehr W., Cremers F.P., Casey J.R., Bhattacharya S.S., Zhang K.;
RT   "Mutant carbonic anhydrase 4 impairs pH regulation and causes retinal
RT   photoreceptor degeneration.";
RL   Hum. Mol. Genet. 14:255-265(2005).
RN   [22]
RP   MUTAGENESIS OF TYR-477; ASP-493; ALA-494; GLU-503; SER-504; GLU-536;
RP   GLU-552; ARG-554; ARG-582; GLU-586; ASP-599; ALA-600; LYS-602; LYS-603;
RP   ASP-691; PHE-700; LYS-711; LYS-712; LYS-714; THR-715; THR-721; ARG-724;
RP   LYS-725; SER-728; ASP-729; ASP-743; ASP-749; LYS-752; ARG-766; GLU-775;
RP   ASP-798; 808-ARG--LYS-809; 814-LYS--LYS-815; HIS-820; ASP-822; HIS-851;
RP   ASP-853; 858-GLU--GLU-860; 875-GLU--ARG-877; LYS-898; 925-ARG--LYS-927;
RP   ARG-948; ARG-949; HIS-951; LYS-968 AND ARG-987.
RX   PubMed=15817634; DOI=10.1113/jphysiol.2005.084988;
RA   Abuladze N., Azimov R., Newman D., Sassani P., Liu W., Tatishchev S.,
RA   Pushkin A., Kurtz I.;
RT   "Critical amino acid residues involved in the electrogenic sodium-
RT   bicarbonate cotransporter kNBC1-mediated transport.";
RL   J. Physiol. (Lond.) 565:717-730(2005).
RN   [23]
RP   FUNCTION, FUNCTION (ISOFORM 2), AND INTERACTION WITH AHCYL1 (ISOFORM 1).
RX   PubMed=16769890; DOI=10.1073/pnas.0602250103;
RA   Shirakabe K., Priori G., Yamada H., Ando H., Horita S., Fujita T.,
RA   Fujimoto I., Mizutani A., Seki G., Mikoshiba K.;
RT   "IRBIT, an inositol 1,4,5-trisphosphate receptor-binding protein,
RT   specifically binds to and activates pancreas-type Na+/HCO3-cotransporter 1
RT   (pNBC1).";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:9542-9547(2006).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-254; SER-257 AND SER-1034,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [25]
RP   DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-641 AND ASN-661.
RX   PubMed=25568315; DOI=10.1074/jbc.m114.619320;
RA   Zhu Q., Kao L., Azimov R., Abuladze N., Newman D., Kurtz I.;
RT   "Interplay between disulfide bonding and N-glycosylation defines SLC4 Na+-
RT   coupled transporter extracellular topography.";
RL   J. Biol. Chem. 290:5391-5404(2015).
RN   [26] {ECO:0007744|PDB:6CAA}
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.90 ANGSTROMS) OF 77-1079, FUNCTION,
RP   SUBUNIT, SUBCELLULAR LOCATION, TOPOLOGY, AND MUTAGENESIS OF SER-527;
RP   527-SER--THR-529; ASP-798; THR-802; VAL-842; ALA-844; THR-845 AND ILE-847.
RX   PubMed=29500354; DOI=10.1038/s41467-018-03271-3;
RA   Huynh K.W., Jiang J., Abuladze N., Tsirulnikov K., Kao L., Shao X.,
RA   Newman D., Azimov R., Pushkin A., Zhou Z.H., Kurtz I.;
RT   "CryoEM structure of the human SLC4A4 sodium-coupled acid-base transporter
RT   NBCe1.";
RL   Nat. Commun. 9:900-900(2018).
RN   [27]
RP   VARIANTS PRTA-OA SER-342 AND HIS-554.
RX   PubMed=10545938; DOI=10.1038/15440;
RA   Igarashi T., Inatomi J., Sekine T., Cha S.H., Kanai Y., Kunimi M.,
RA   Tsukamoto K., Satoh H., Shimadzu M., Tozawa F., Mori T., Shiobara M.,
RA   Seki G., Endou H.;
RT   "Mutations in SLC4A4 cause permanent isolated proximal renal tubular
RT   acidosis with ocular abnormalities.";
RL   Nat. Genet. 23:264-266(1999).
RN   [28]
RP   VARIANT PRTA-OA LEU-471.
RX   PubMed=15471865; DOI=10.1074/jbc.m406591200;
RA   Dinour D., Chang M.-H., Satoh J., Smith B.L., Angle N., Knecht A.,
RA   Serban I., Holtzman E.J., Romero M.F.;
RT   "A novel missense mutation in the sodium bicarbonate cotransporter
RT   (NBCe1/SLC4A4) causes proximal tubular acidosis and glaucoma through ion
RT   transport defects.";
RL   J. Biol. Chem. 279:52238-52246(2004).
RN   [29]
RP   VARIANTS PRTA-OA SER-342; LEU-471 AND HIS-554, AND MUTAGENESIS OF GLU-135.
RX   PubMed=15713912; DOI=10.1152/ajprenal.00032.2005;
RA   Li H.C., Szigligeti P., Worrell R.T., Matthews J.B., Conforti L.,
RA   Soleimani M.;
RT   "Missense mutations in Na+:HCO3- cotransporter NBC1 show abnormal
RT   trafficking in polarized kidney cells: a basis of proximal renal tubular
RT   acidosis.";
RL   Am. J. Physiol. 289:F61-F71(2005).
RN   [30]
RP   VARIANTS PRTA-OA SER-342; SER-529; HIS-554; VAL-843 AND CYS-925.
RX   PubMed=15930088; DOI=10.1681/asn.2004080667;
RA   Horita S., Yamada H., Inatomi J., Moriyama N., Sekine T., Igarashi T.,
RA   Endo Y., Dasouki M., Ekim M., Al-Gazali L., Shimadzu M., Seki G.,
RA   Fujita T.;
RT   "Functional analysis of NBC1 mutants associated with proximal renal tubular
RT   acidosis and ocular abnormalities.";
RL   J. Am. Soc. Nephrol. 16:2270-2278(2005).
RN   [31]
RP   VARIANT PRTA-OA PRO-566, CHARACTERIZATION OF VARIANT PRTA-OA PRO-566,
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=16636648;
RA   Demirci F.Y., Chang M.H., Mah T.S., Romero M.F., Gorin M.B.;
RT   "Proximal renal tubular acidosis and ocular pathology: a novel missense
RT   mutation in the gene (SLC4A4) for sodium bicarbonate cotransporter protein
RT   (NBCe1).";
RL   Mol. Vis. 12:324-330(2006).
RN   [32]
RP   VARIANT PRTA-OA ARG-530, CHARACTERIZATION OF VARIANTS PRTA-OA SER-342
RP   SER-529; ARG-530 AND PRO-566, FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=17661077; DOI=10.1007/s00424-007-0319-y;
RA   Suzuki M., Vaisbich M.H., Yamada H., Horita S., Li Y., Sekine T.,
RA   Moriyama N., Igarashi T., Endo Y., Cardoso T.P., de Sa L.C., Koch V.H.,
RA   Seki G., Fujita T.;
RT   "Functional analysis of a novel missense NBC1 mutation and of other
RT   mutations causing proximal renal tubular acidosis.";
RL   Pflugers Arch. 455:583-593(2008).
CC   -!- FUNCTION: Electrogenic sodium/bicarbonate cotransporter with a
CC       Na(+):HCO3(-) stoichiometry varying from 1:2 to 1:3. May regulate
CC       bicarbonate influx/efflux at the basolateral membrane of cells and
CC       regulate intracellular pH. {ECO:0000269|PubMed:10069984,
CC       ECO:0000269|PubMed:12907161, ECO:0000269|PubMed:16636648,
CC       ECO:0000269|PubMed:16769890, ECO:0000269|PubMed:17661077,
CC       ECO:0000269|PubMed:29500354, ECO:0000269|PubMed:9235899,
CC       ECO:0000269|PubMed:9651366}.
CC   -!- FUNCTION: [Isoform 2]: May have a higher activity than isoform 1.
CC       {ECO:0000269|PubMed:16769890}.
CC   -!- ACTIVITY REGULATION: Inhibited by stilbene derivatives and regulated by
CC       cyclic AMP.
CC   -!- SUBUNIT: Homodimer (PubMed:29500354). Interacts with CA2/carbonic
CC       anhydrase 2 and CA4/carbonic anhydrase 4 which may regulate transporter
CC       activity (PubMed:12411514, PubMed:14567693, PubMed:15218065,
CC       PubMed:15563508). Isoform 1 but not isoform 2 interacts with AHCYL1
CC       (via PEST domain when phosphorylated); the interaction increases SLC4A4
CC       isoform 1 activity (PubMed:16769890). Interacts with AHCYL2 (By
CC       similarity). {ECO:0000250|UniProtKB:O88343,
CC       ECO:0000250|UniProtKB:Q9GL77, ECO:0000269|PubMed:12411514,
CC       ECO:0000269|PubMed:14567693, ECO:0000269|PubMed:15218065,
CC       ECO:0000269|PubMed:15563508, ECO:0000269|PubMed:16769890,
CC       ECO:0000269|PubMed:29500354}.
CC   -!- INTERACTION:
CC       Q9Y6R1-1; Q9Y6R1-1: SLC4A4; NbExp=2; IntAct=EBI-6859278, EBI-6859278;
CC       Q9Y6R1-1; P48283: CA4; Xeno; NbExp=2; IntAct=EBI-6859278, EBI-6859264;
CC   -!- SUBCELLULAR LOCATION: Basolateral cell membrane
CC       {ECO:0000269|PubMed:12907161, ECO:0000269|PubMed:15273250,
CC       ECO:0000269|PubMed:16636648, ECO:0000269|PubMed:17661077,
CC       ECO:0000305|PubMed:12534288, ECO:0000305|PubMed:29500354}; Multi-pass
CC       membrane protein {ECO:0000269|PubMed:12534288,
CC       ECO:0000305|PubMed:29500354}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1; Synonyms=hcNBC, hhNBC, hNBC1, pNBC, pNCB1, pNBC-1, NBC1b;
CC         IsoId=Q9Y6R1-1; Sequence=Displayed;
CC       Name=2; Synonyms=hkNBC, hkNBCe1, kNBC, kNBC1, kNBC-1, NBC1a;
CC         IsoId=Q9Y6R1-2; Sequence=VSP_016704, VSP_016705;
CC       Name=3;
CC         IsoId=Q9Y6R1-3; Sequence=VSP_016704, VSP_016705, VSP_016706,
CC                                  VSP_016707;
CC       Name=4;
CC         IsoId=Q9Y6R1-4; Sequence=VSP_016708;
CC       Name=5;
CC         IsoId=Q9Y6R1-5; Sequence=VSP_041003;
CC   -!- TISSUE SPECIFICITY: Isoform 1 is expressed in pancreas and to a lower
CC       extent in heart, skeletal muscle, liver, parotid salivary glands,
CC       prostate, colon, stomach, thyroid, brain and spinal chord. Corneal
CC       endothelium cells express only isoform 1 (at protein level). Isoform 2
CC       is specifically expressed in kidney at the level of proximal tubules.
CC       {ECO:0000269|PubMed:10069984, ECO:0000269|PubMed:11743927,
CC       ECO:0000269|PubMed:12907161, ECO:0000269|PubMed:14559244,
CC       ECO:0000269|PubMed:15329059, ECO:0000269|PubMed:9235899,
CC       ECO:0000269|PubMed:9651366}.
CC   -!- PTM: Phosphorylation of Ser-1026 by PKA increases the binding of CA2
CC       and changes the Na(+):HCO3(-) stoichiometry of the transporter from 3:1
CC       to 2:1. Phosphorylated in presence of STK39 and dephosphorylated in
CC       presence of PP1 phosphatase; phosphorylation seems to inhibit SLC4A4
CC       activity. {ECO:0000250|UniProtKB:O88343, ECO:0000269|PubMed:11744745,
CC       ECO:0000269|PubMed:12730338}.
CC   -!- PTM: N-glycosylation is not necessary for the transporter basic
CC       functions. {ECO:0000269|PubMed:12604466}.
CC   -!- DISEASE: Renal tubular acidosis, proximal, with ocular abnormalities
CC       and mental retardation (pRTA-OA) [MIM:604278]: An extremely rare
CC       autosomal recessive syndrome characterized by short stature, profound
CC       proximal renal tubular acidosis, mental retardation, bilateral
CC       glaucoma, cataracts and bandkeratopathy. pRTA is due to a failure of
CC       the proximal tubular cells to reabsorb filtered bicarbonate from the
CC       urine, leading to urinary bicarbonate wasting and subsequent acidemia.
CC       {ECO:0000269|PubMed:10545938, ECO:0000269|PubMed:15471865,
CC       ECO:0000269|PubMed:15713912, ECO:0000269|PubMed:15930088,
CC       ECO:0000269|PubMed:16636648, ECO:0000269|PubMed:17661077}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Note=Loss of interaction with and stimulation by CA4 is the
CC       cause of retinitis pigmentosa type 17 (RP17).
CC   -!- SIMILARITY: Belongs to the anion exchanger (TC 2.A.31) family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF007216; AAC51645.1; -; mRNA.
DR   EMBL; AF011390; AAC39840.1; -; mRNA.
DR   EMBL; AF053753; AAF21718.1; -; mRNA.
DR   EMBL; AF053754; AAF21719.1; -; mRNA.
DR   EMBL; AF069510; AAD42020.1; -; mRNA.
DR   EMBL; AF310248; AAG47773.1; -; mRNA.
DR   EMBL; AF157492; AAF80343.1; -; mRNA.
DR   EMBL; AB470072; BAH58226.1; -; mRNA.
DR   EMBL; AC019089; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC079230; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC096713; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC110783; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC112226; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC030977; AAH30977.1; -; mRNA.
DR   CCDS; CCDS3549.1; -. [Q9Y6R1-2]
DR   CCDS; CCDS43236.1; -. [Q9Y6R1-1]
DR   CCDS; CCDS47071.1; -. [Q9Y6R1-5]
DR   RefSeq; NP_001091954.1; NM_001098484.2. [Q9Y6R1-1]
DR   RefSeq; NP_003750.1; NM_003759.3. [Q9Y6R1-2]
DR   PDB; 6CAA; EM; 3.90 A; A/B=77-1079.
DR   PDBsum; 6CAA; -.
DR   SMR; Q9Y6R1; -.
DR   BioGRID; 114219; 5.
DR   DIP; DIP-59373N; -.
DR   IntAct; Q9Y6R1; 9.
DR   MINT; Q9Y6R1; -.
DR   STRING; 9606.ENSP00000393557; -.
DR   DrugBank; DB01390; Sodium bicarbonate.
DR   TCDB; 2.A.31.2.12; the anion exchanger (ae) family.
DR   GlyGen; Q9Y6R1; 2 sites.
DR   iPTMnet; Q9Y6R1; -.
DR   PhosphoSitePlus; Q9Y6R1; -.
DR   SwissPalm; Q9Y6R1; -.
DR   BioMuta; SLC4A4; -.
DR   DMDM; 74721543; -.
DR   jPOST; Q9Y6R1; -.
DR   MassIVE; Q9Y6R1; -.
DR   PaxDb; Q9Y6R1; -.
DR   PeptideAtlas; Q9Y6R1; -.
DR   PRIDE; Q9Y6R1; -.
DR   ProteomicsDB; 86772; -. [Q9Y6R1-1]
DR   ProteomicsDB; 86773; -. [Q9Y6R1-2]
DR   ProteomicsDB; 86774; -. [Q9Y6R1-3]
DR   ProteomicsDB; 86775; -. [Q9Y6R1-4]
DR   ProteomicsDB; 86776; -. [Q9Y6R1-5]
DR   Antibodypedia; 24400; 194 antibodies.
DR   DNASU; 8671; -.
DR   Ensembl; ENST00000264485; ENSP00000264485; ENSG00000080493. [Q9Y6R1-1]
DR   Ensembl; ENST00000340595; ENSP00000344272; ENSG00000080493. [Q9Y6R1-2]
DR   Ensembl; ENST00000351898; ENSP00000307349; ENSG00000080493. [Q9Y6R1-4]
DR   Ensembl; ENST00000425175; ENSP00000393557; ENSG00000080493. [Q9Y6R1-5]
DR   Ensembl; ENST00000512686; ENSP00000422400; ENSG00000080493. [Q9Y6R1-3]
DR   Ensembl; ENST00000649996; ENSP00000497468; ENSG00000080493. [Q9Y6R1-1]
DR   GeneID; 8671; -.
DR   KEGG; hsa:8671; -.
DR   UCSC; uc003hfy.4; human. [Q9Y6R1-1]
DR   CTD; 8671; -.
DR   DisGeNET; 8671; -.
DR   GeneCards; SLC4A4; -.
DR   HGNC; HGNC:11030; SLC4A4.
DR   HPA; ENSG00000080493; Tissue enhanced (kidney, pancreas).
DR   MalaCards; SLC4A4; -.
DR   MIM; 603345; gene.
DR   MIM; 604278; phenotype.
DR   neXtProt; NX_Q9Y6R1; -.
DR   OpenTargets; ENSG00000080493; -.
DR   Orphanet; 93607; Autosomal recessive proximal renal tubular acidosis.
DR   PharmGKB; PA35898; -.
DR   VEuPathDB; HostDB:ENSG00000080493.13; -.
DR   eggNOG; KOG1172; Eukaryota.
DR   GeneTree; ENSGT00940000156290; -.
DR   HOGENOM; CLU_002289_5_0_1; -.
DR   InParanoid; Q9Y6R1; -.
DR   OMA; VSSTDMY; -.
DR   OrthoDB; 265068at2759; -.
DR   PhylomeDB; Q9Y6R1; -.
DR   TreeFam; TF313630; -.
DR   PathwayCommons; Q9Y6R1; -.
DR   Reactome; R-HSA-425381; Bicarbonate transporters.
DR   Reactome; R-HSA-5619054; Defective SLC4A4 causes renal tubular acidosis, proximal, with ocular abnormalities and mental retardation (pRTA-OA).
DR   BioGRID-ORCS; 8671; 6 hits in 980 CRISPR screens.
DR   ChiTaRS; SLC4A4; human.
DR   GeneWiki; SLC4A4; -.
DR   GenomeRNAi; 8671; -.
DR   Pharos; Q9Y6R1; Tbio.
DR   PRO; PR:Q9Y6R1; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   RNAct; Q9Y6R1; protein.
DR   Bgee; ENSG00000080493; Expressed in duodenum and 215 other tissues.
DR   ExpressionAtlas; Q9Y6R1; baseline and differential.
DR   Genevisible; Q9Y6R1; HS.
DR   GO; GO:0016323; C:basolateral plasma membrane; IDA:UniProtKB.
DR   GO; GO:0009986; C:cell surface; IDA:ARUK-UCL.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0016020; C:membrane; IDA:ARUK-UCL.
DR   GO; GO:0005886; C:plasma membrane; IDA:ARUK-UCL.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0005452; F:inorganic anion exchanger activity; IEA:InterPro.
DR   GO; GO:0008510; F:sodium:bicarbonate symporter activity; IMP:UniProtKB.
DR   GO; GO:0015293; F:symporter activity; IMP:ARUK-UCL.
DR   GO; GO:0022857; F:transmembrane transporter activity; IBA:GO_Central.
DR   GO; GO:0015701; P:bicarbonate transport; IDA:ARUK-UCL.
DR   GO; GO:0050801; P:ion homeostasis; IBA:GO_Central.
DR   GO; GO:0045821; P:positive regulation of glycolytic process; IGI:ARUK-UCL.
DR   GO; GO:0051453; P:regulation of intracellular pH; IDA:ARUK-UCL.
DR   GO; GO:0042391; P:regulation of membrane potential; IDA:ARUK-UCL.
DR   GO; GO:0036376; P:sodium ion export across plasma membrane; IMP:ARUK-UCL.
DR   GO; GO:0035725; P:sodium ion transmembrane transport; IDA:ARUK-UCL.
DR   GO; GO:0006814; P:sodium ion transport; IDA:UniProtKB.
DR   GO; GO:0055085; P:transmembrane transport; IMP:ARUK-UCL.
DR   GO; GO:0150104; P:transport across blood-brain barrier; NAS:ARUK-UCL.
DR   Gene3D; 3.40.930.10; -; 1.
DR   InterPro; IPR013769; Band3_cytoplasmic_dom.
DR   InterPro; IPR011531; HCO3_transpt_C.
DR   InterPro; IPR003020; HCO3_transpt_euk.
DR   InterPro; IPR003024; Na/HCO3_transpt.
DR   InterPro; IPR016152; PTrfase/Anion_transptr.
DR   PANTHER; PTHR11453; PTHR11453; 1.
DR   Pfam; PF07565; Band_3_cyto; 1.
DR   Pfam; PF00955; HCO3_cotransp; 1.
DR   PRINTS; PR01231; HCO3TRNSPORT.
DR   PRINTS; PR01232; NAHCO3TRSPRT.
DR   SUPFAM; SSF55804; SSF55804; 1.
DR   TIGRFAMs; TIGR00834; ae; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell membrane; Disease variant;
KW   Disulfide bond; Glycoprotein; Ion transport; Membrane; Phosphoprotein;
KW   Reference proteome; Retinitis pigmentosa; Sodium; Sodium transport;
KW   Symport; Transmembrane; Transmembrane helix; Transport.
FT   CHAIN           1..1079
FT                   /note="Electrogenic sodium bicarbonate cotransporter 1"
FT                   /id="PRO_0000079227"
FT   TOPO_DOM        1..466
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:12534288,
FT                   ECO:0000305|PubMed:29500354"
FT   TRANSMEM        467..491
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000305|PubMed:12534288,
FT                   ECO:0000305|PubMed:29500354"
FT   TOPO_DOM        492..501
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305|PubMed:12534288,
FT                   ECO:0000305|PubMed:29500354"
FT   TRANSMEM        502..520
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000305|PubMed:12534288,
FT                   ECO:0000305|PubMed:29500354"
FT   TOPO_DOM        521
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305|PubMed:12534288,
FT                   ECO:0000305|PubMed:29500354"
FT   TRANSMEM        522..542
FT                   /note="Discontinuously helical; Name=3"
FT                   /evidence="ECO:0000305|PubMed:29500354"
FT   TOPO_DOM        543..550
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:12534288,
FT                   ECO:0000305|PubMed:29500354"
FT   TRANSMEM        551..571
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000305|PubMed:12534288,
FT                   ECO:0000305|PubMed:29500354"
FT   TOPO_DOM        572..585
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305|PubMed:12534288,
FT                   ECO:0000305|PubMed:29500354"
FT   TRANSMEM        586..609
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000305|PubMed:29500354"
FT   TOPO_DOM        610..692
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:12534288,
FT                   ECO:0000305|PubMed:29500354"
FT   TRANSMEM        693..710
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000305|PubMed:12534288,
FT                   ECO:0000305|PubMed:29500354"
FT   TOPO_DOM        711..725
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305|PubMed:12534288,
FT                   ECO:0000305|PubMed:29500354"
FT   TRANSMEM        726..745
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000305|PubMed:12534288,
FT                   ECO:0000305|PubMed:29500354"
FT   TOPO_DOM        746..779
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305|PubMed:12534288,
FT                   ECO:0000305|PubMed:29500354"
FT   TRANSMEM        780..807
FT                   /note="Helical; Name=8"
FT                   /evidence="ECO:0000305|PubMed:12534288,
FT                   ECO:0000305|PubMed:29500354"
FT   TOPO_DOM        808..819
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305|PubMed:12534288,
FT                   ECO:0000305|PubMed:29500354"
FT   TRANSMEM        820..836
FT                   /note="Helical; Name=9"
FT                   /evidence="ECO:0000305|PubMed:12534288,
FT                   ECO:0000305|PubMed:29500354"
FT   TOPO_DOM        837
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305|PubMed:12534288,
FT                   ECO:0000305|PubMed:29500354"
FT   TRANSMEM        838..855
FT                   /note="Discontinuously helical; Name=10"
FT                   /evidence="ECO:0000305|PubMed:29500354"
FT   TOPO_DOM        856..877
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:12534288,
FT                   ECO:0000305|PubMed:29500354"
FT   TRANSMEM        878..894
FT                   /note="Helical; Name=11"
FT                   /evidence="ECO:0000305|PubMed:12534288,
FT                   ECO:0000305|PubMed:29500354"
FT   TOPO_DOM        895..901
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305|PubMed:12534288,
FT                   ECO:0000305|PubMed:29500354"
FT   TRANSMEM        902..918
FT                   /note="Helical; Name=12"
FT                   /evidence="ECO:0000305|PubMed:29500354"
FT   TOPO_DOM        919..960
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:12534288,
FT                   ECO:0000305|PubMed:29500354"
FT   INTRAMEM        961..986
FT                   /note="Discontinuously helical"
FT                   /evidence="ECO:0000305|PubMed:29500354"
FT   TOPO_DOM        987..1079
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:12534288,
FT                   ECO:0000305|PubMed:29500354"
FT   REGION          1..62
FT                   /note="Required for interaction with AHCYL1"
FT                   /evidence="ECO:0000269|PubMed:16769890"
FT   REGION          748..779
FT                   /note="Interaction with CA4"
FT   REGION          1002..1004
FT                   /note="CA2-binding"
FT   REGION          1030..1033
FT                   /note="CA2-binding"
FT   REGION          1057..1059
FT                   /note="Required for basolateral targeting"
FT   COMPBIAS        1009..1024
FT                   /note="Lys-rich"
FT   MOD_RES         30
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:O88343"
FT   MOD_RES         49
FT                   /note="Phosphothreonine; by PKA"
FT                   /evidence="ECO:0000269|PubMed:12730338"
FT   MOD_RES         61
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O88343"
FT   MOD_RES         65
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O88343"
FT   MOD_RES         68
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O88343"
FT   MOD_RES         223
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O88343"
FT   MOD_RES         232
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O88343"
FT   MOD_RES         233
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O88343"
FT   MOD_RES         245
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O88343"
FT   MOD_RES         249
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9JI66"
FT   MOD_RES         254
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         256
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O88343"
FT   MOD_RES         257
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         262
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O88343"
FT   MOD_RES         1026
FT                   /note="Phosphoserine; by PKA"
FT                   /evidence="ECO:0000269|PubMed:11744745"
FT   MOD_RES         1029
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O88343"
FT   MOD_RES         1034
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         1044
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O88343"
FT   MOD_RES         1069
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9JI66"
FT   CARBOHYD        641
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:25568315"
FT   CARBOHYD        661
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:25568315"
FT   DISULFID        627..629
FT                   /evidence="ECO:0000269|PubMed:25568315"
FT   DISULFID        674..686
FT                   /evidence="ECO:0000269|PubMed:25568315"
FT   VAR_SEQ         1..44
FT                   /note="Missing (in isoform 2 and isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:9235899"
FT                   /id="VSP_016704"
FT   VAR_SEQ         45..85
FT                   /note="HKRKTGHKEKKEKERISENYSDKSDIENADESSSSILKPLI -> MSTENVE
FT                   GKPSNLGERGRARSSTFLRVVQPMFNHSIFTSAV (in isoform 2 and
FT                   isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:9235899"
FT                   /id="VSP_016705"
FT   VAR_SEQ         635..690
FT                   /note="ANISISNDTTLAPEYLPTMSSTDMYHNTTFDWAFLSKKECSKYGGNLVGNNC
FT                   NFVP -> GEGITLCVYARFVFGGRCRLHACKFSTCCHGPQELVLFFSLKNSATEFDVS
FT                   LPEVF (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_016706"
FT   VAR_SEQ         691..1079
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_016707"
FT   VAR_SEQ         813..896
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|Ref.5"
FT                   /id="VSP_016708"
FT   VAR_SEQ         1034..1079
FT                   /note="SDCPYSEKVPSIKIPMDIMEQQPFLSDSKPSDRERSPTFLERHTSC -> EK
FT                   DHQHSLNATHHADKIPFLQSLGMPSPPRTPVKVVPQIRIELEPEDNDYFWRSKGTETTL
FT                   (in isoform 5)"
FT                   /evidence="ECO:0000303|Ref.6"
FT                   /id="VSP_041003"
FT   VARIANT         342
FT                   /note="R -> S (in pRTA-OA; decreased localization to the
FT                   basolateral membrane; mistargeting to the apical membrane
FT                   probably explains the loss of the cotransporter activity;
FT                   dbSNP:rs121908856)"
FT                   /evidence="ECO:0000269|PubMed:10545938,
FT                   ECO:0000269|PubMed:15713912, ECO:0000269|PubMed:15930088,
FT                   ECO:0000303|PubMed:17661077"
FT                   /id="VAR_024751"
FT   VARIANT         471
FT                   /note="S -> L (in pRTA-OA; mistargeting to the apical
FT                   membrane and altered function)"
FT                   /evidence="ECO:0000269|PubMed:15471865,
FT                   ECO:0000269|PubMed:15713912"
FT                   /id="VAR_024752"
FT   VARIANT         529
FT                   /note="T -> S (in pRTA-OA; decreased cotransporter
FT                   activity)"
FT                   /evidence="ECO:0000269|PubMed:15930088,
FT                   ECO:0000303|PubMed:17661077"
FT                   /id="VAR_024753"
FT   VARIANT         530
FT                   /note="G -> R (in pRTA-OA; decreased cotransporter
FT                   activity; no effect on localization to the basolateral
FT                   membrane)"
FT                   /evidence="ECO:0000303|PubMed:17661077"
FT                   /id="VAR_071661"
FT   VARIANT         554
FT                   /note="R -> H (in pRTA-OA; mistargeting and altered
FT                   function; dbSNP:rs121908857)"
FT                   /evidence="ECO:0000269|PubMed:10545938,
FT                   ECO:0000269|PubMed:15713912, ECO:0000269|PubMed:15930088"
FT                   /id="VAR_024754"
FT   VARIANT         566
FT                   /note="L -> P (in pRTA-OA; loss of localization to the
FT                   plasma membrane; the retention in the cytoplasm probably
FT                   explains the loss of the cotransporter activity)"
FT                   /evidence="ECO:0000269|PubMed:16636648,
FT                   ECO:0000303|PubMed:17661077"
FT                   /id="VAR_071662"
FT   VARIANT         843
FT                   /note="A -> V (in pRTA-OA; altered function)"
FT                   /evidence="ECO:0000269|PubMed:15930088"
FT                   /id="VAR_024755"
FT   VARIANT         925
FT                   /note="R -> C (in pRTA-OA; altered function;
FT                   dbSNP:rs1203164637)"
FT                   /evidence="ECO:0000269|PubMed:15930088"
FT                   /id="VAR_024756"
FT   MUTAGEN         49
FT                   /note="T->A: Loss of conductance regulation by cAMP;
FT                   isoform 1."
FT                   /evidence="ECO:0000269|PubMed:12730338"
FT   MUTAGEN         49
FT                   /note="T->D: Loss of conductance regulation by cAMP;
FT                   isoform 1."
FT                   /evidence="ECO:0000269|PubMed:12730338"
FT   MUTAGEN         135
FT                   /note="E->R: Mistargeting and altered function."
FT                   /evidence="ECO:0000269|PubMed:15713912"
FT   MUTAGEN         477
FT                   /note="Y->F: Moderate reduction of the sodium-dependent ion
FT                   transport activity."
FT                   /evidence="ECO:0000269|PubMed:15817634"
FT   MUTAGEN         493
FT                   /note="D->N: Prevents membrane targeting."
FT                   /evidence="ECO:0000269|PubMed:15817634"
FT   MUTAGEN         494
FT                   /note="A->K: Prevents membrane targeting."
FT                   /evidence="ECO:0000269|PubMed:15817634"
FT   MUTAGEN         503
FT                   /note="E->Q: Strong reduction of the sodium-dependent ion
FT                   transport activity."
FT                   /evidence="ECO:0000269|PubMed:15817634"
FT   MUTAGEN         504
FT                   /note="S->L: Prevents membrane targeting."
FT                   /evidence="ECO:0000269|PubMed:15817634"
FT   MUTAGEN         527..529
FT                   /note="SST->GFS: Confers anion exchange activity; when
FT                   associated with E-798; S-842; T-844 and R-847."
FT                   /evidence="ECO:0000269|PubMed:29500354"
FT   MUTAGEN         527
FT                   /note="S->C: Severely reduces transporter activity."
FT                   /evidence="ECO:0000269|PubMed:29500354"
FT   MUTAGEN         536
FT                   /note="E->Q: Prevents membrane targeting."
FT                   /evidence="ECO:0000269|PubMed:15817634"
FT   MUTAGEN         552
FT                   /note="E->N: Prevents membrane targeting."
FT                   /evidence="ECO:0000269|PubMed:15817634"
FT   MUTAGEN         554
FT                   /note="R->D: Prevents membrane targeting."
FT                   /evidence="ECO:0000269|PubMed:15817634"
FT   MUTAGEN         582
FT                   /note="R->N: Moderate reduction of the sodium-dependent ion
FT                   transport activity."
FT                   /evidence="ECO:0000269|PubMed:15817634"
FT   MUTAGEN         582
FT                   /note="R->Q: Strong reduction of the sodium-dependent ion
FT                   transport activity."
FT                   /evidence="ECO:0000269|PubMed:15817634"
FT   MUTAGEN         586
FT                   /note="E->Q: Moderate reduction of the sodium-dependent ion
FT                   transport activity."
FT                   /evidence="ECO:0000269|PubMed:15817634"
FT   MUTAGEN         599
FT                   /note="D->N: Moderate reduction of the sodium-dependent ion
FT                   transport activity."
FT                   /evidence="ECO:0000269|PubMed:15817634"
FT   MUTAGEN         600
FT                   /note="A->T: Strong reduction of the sodium-dependent ion
FT                   transport activity."
FT                   /evidence="ECO:0000269|PubMed:15817634"
FT   MUTAGEN         602
FT                   /note="K->Q: Moderate reduction of the sodium-dependent ion
FT                   transport activity."
FT                   /evidence="ECO:0000269|PubMed:15817634"
FT   MUTAGEN         603
FT                   /note="K->Q: Strong reduction of the sodium-dependent ion
FT                   transport activity."
FT                   /evidence="ECO:0000269|PubMed:15817634"
FT   MUTAGEN         691
FT                   /note="D->R: Strong reduction of the sodium-dependent ion
FT                   transport activity."
FT                   /evidence="ECO:0000269|PubMed:15817634"
FT   MUTAGEN         700
FT                   /note="F->M: Strong reduction of the sodium-dependent ion
FT                   transport activity."
FT                   /evidence="ECO:0000269|PubMed:15817634"
FT   MUTAGEN         711
FT                   /note="K->E,N,Q: Strong reduction of the sodium-dependent
FT                   ion transport activity."
FT                   /evidence="ECO:0000269|PubMed:15817634"
FT   MUTAGEN         711
FT                   /note="K->R: No effect on the sodium-dependent ion
FT                   transport activity."
FT                   /evidence="ECO:0000269|PubMed:15817634"
FT   MUTAGEN         712
FT                   /note="K->N: Strong reduction of the sodium-dependent ion
FT                   transport activity."
FT                   /evidence="ECO:0000269|PubMed:15817634"
FT   MUTAGEN         714
FT                   /note="K->Q: Moderate reduction of the sodium-dependent ion
FT                   transport activity."
FT                   /evidence="ECO:0000269|PubMed:15817634"
FT   MUTAGEN         715
FT                   /note="T->N: Strong reduction of the sodium-dependent ion
FT                   transport activity."
FT                   /evidence="ECO:0000269|PubMed:15817634"
FT   MUTAGEN         721
FT                   /note="T->G: Moderate reduction of the sodium-dependent ion
FT                   transport activity."
FT                   /evidence="ECO:0000269|PubMed:15817634"
FT   MUTAGEN         724
FT                   /note="R->E: Strong reduction of the sodium-dependent ion
FT                   transport activity."
FT                   /evidence="ECO:0000269|PubMed:15817634"
FT   MUTAGEN         725
FT                   /note="K->N: Strong reduction of the sodium-dependent ion
FT                   transport activity."
FT                   /evidence="ECO:0000269|PubMed:15817634"
FT   MUTAGEN         728
FT                   /note="S->G: Strong reduction of the sodium-dependent ion
FT                   transport activity."
FT                   /evidence="ECO:0000269|PubMed:15817634"
FT   MUTAGEN         729
FT                   /note="D->N,R: Strong reduction of the sodium-dependent ion
FT                   transport activity."
FT                   /evidence="ECO:0000269|PubMed:15817634"
FT   MUTAGEN         743
FT                   /note="D->K,N: Prevents membrane targeting."
FT                   /evidence="ECO:0000269|PubMed:15817634"
FT   MUTAGEN         749
FT                   /note="D->N: Moderate reduction of the sodium-dependent ion
FT                   transport activity."
FT                   /evidence="ECO:0000269|PubMed:15817634"
FT   MUTAGEN         752
FT                   /note="K->Q: Prevents membrane targeting."
FT                   /evidence="ECO:0000269|PubMed:15817634"
FT   MUTAGEN         766
FT                   /note="R->Q: Moderate reduction of the sodium-dependent ion
FT                   transport activity."
FT                   /evidence="ECO:0000269|PubMed:15817634"
FT   MUTAGEN         767
FT                   /note="G->T: Alters interaction with CA4."
FT                   /evidence="ECO:0000269|PubMed:14567693"
FT   MUTAGEN         775
FT                   /note="E->N: Moderate reduction of the sodium-dependent ion
FT                   transport activity."
FT                   /evidence="ECO:0000269|PubMed:15817634"
FT   MUTAGEN         798
FT                   /note="D->C: Abolishes transporter activity."
FT                   /evidence="ECO:0000269|PubMed:29500354"
FT   MUTAGEN         798
FT                   /note="D->E: Severely reduces transporter activity. Confers
FT                   anion exchange activity; when associated with SST-527--529-
FT                   GFS; S-842; T-844 and R-847."
FT                   /evidence="ECO:0000269|PubMed:29500354"
FT   MUTAGEN         798
FT                   /note="D->N,R: Strong reduction of the sodium-dependent ion
FT                   transport activity."
FT                   /evidence="ECO:0000269|PubMed:15817634"
FT   MUTAGEN         802
FT                   /note="T->C: Abolishes transporter activity."
FT                   /evidence="ECO:0000269|PubMed:29500354"
FT   MUTAGEN         808..809
FT                   /note="RK->NN: Strong reduction of the sodium-dependent ion
FT                   transport activity."
FT                   /evidence="ECO:0000269|PubMed:15817634"
FT   MUTAGEN         814..815
FT                   /note="KK->NN: Moderate reduction of the sodium-dependent
FT                   ion transport activity."
FT                   /evidence="ECO:0000269|PubMed:15817634"
FT   MUTAGEN         820
FT                   /note="H->D,N,S,R: Moderate reduction of the sodium-
FT                   dependent ion transport activity."
FT                   /evidence="ECO:0000269|PubMed:15817634"
FT   MUTAGEN         822
FT                   /note="D->N: Moderate reduction of the sodium-dependent ion
FT                   transport activity."
FT                   /evidence="ECO:0000269|PubMed:15817634"
FT   MUTAGEN         842
FT                   /note="V->S: Confers anion exchange activity; when
FT                   associated with SST-527--529-GFS; D-798; T-844 and R-847."
FT                   /evidence="ECO:0000269|PubMed:29500354"
FT   MUTAGEN         844
FT                   /note="A->T: Confers anion exchange activity; when
FT                   associated with SST-527--529-GFS; D-798; S-842 and R-847."
FT                   /evidence="ECO:0000269|PubMed:29500354"
FT   MUTAGEN         845
FT                   /note="T->C: Strongly reduces transporter activity."
FT                   /evidence="ECO:0000269|PubMed:29500354"
FT   MUTAGEN         847
FT                   /note="I->R: Abolishes transporter activity. Confers anion
FT                   exchange activity; when associated with SST-527--529-GFS;
FT                   D-798; S-842 and T-844."
FT                   /evidence="ECO:0000269|PubMed:29500354"
FT   MUTAGEN         851
FT                   /note="H->N: Prevents membrane targeting."
FT                   /evidence="ECO:0000269|PubMed:15817634"
FT   MUTAGEN         853
FT                   /note="D->N: Moderate reduction of the sodium-dependent ion
FT                   transport activity."
FT                   /evidence="ECO:0000269|PubMed:15817634"
FT   MUTAGEN         858..860
FT                   /note="ETE->MSK: Moderate reduction of the sodium-dependent
FT                   ion transport activity."
FT                   /evidence="ECO:0000269|PubMed:15817634"
FT   MUTAGEN         875..877
FT                   /note="EQR->QQQ: Prevents membrane targeting."
FT                   /evidence="ECO:0000269|PubMed:15817634"
FT   MUTAGEN         875
FT                   /note="E->Q: Strong reduction of the sodium-dependent ion
FT                   transport activity."
FT   MUTAGEN         898
FT                   /note="K->E: Strong reduction of the sodium-dependent ion
FT                   transport activity."
FT                   /evidence="ECO:0000269|PubMed:15817634"
FT   MUTAGEN         925..927
FT                   /note="RLK->NLN: Prevents membrane targeting."
FT                   /evidence="ECO:0000269|PubMed:15817634"
FT   MUTAGEN         948
FT                   /note="R->E: Strong reduction of the sodium-dependent ion
FT                   transport activity."
FT                   /evidence="ECO:0000269|PubMed:15817634"
FT   MUTAGEN         949
FT                   /note="R->E: Moderate reduction of the sodium-dependent ion
FT                   transport activity."
FT                   /evidence="ECO:0000269|PubMed:15817634"
FT   MUTAGEN         951
FT                   /note="H->D: Moderate reduction of the sodium-dependent ion
FT                   transport activity."
FT                   /evidence="ECO:0000269|PubMed:15817634"
FT   MUTAGEN         951
FT                   /note="H->N,R: Prevents membrane targeting."
FT                   /evidence="ECO:0000269|PubMed:15817634"
FT   MUTAGEN         968
FT                   /note="K->Q: Moderate reduction of the sodium-dependent ion
FT                   transport activity."
FT                   /evidence="ECO:0000269|PubMed:15817634"
FT   MUTAGEN         987
FT                   /note="R->E,N: Moderate reduction of the sodium-dependent
FT                   ion transport activity."
FT                   /evidence="ECO:0000269|PubMed:15817634"
FT   MUTAGEN         1002
FT                   /note="L->N: Partial loss of interaction with CA2."
FT                   /evidence="ECO:0000269|PubMed:15218065"
FT   MUTAGEN         1003
FT                   /note="D->N: Abolishes interaction with CA2."
FT                   /evidence="ECO:0000269|PubMed:15218065"
FT   MUTAGEN         1004
FT                   /note="D->N: Partial loss of interaction with CA2."
FT                   /evidence="ECO:0000269|PubMed:15218065"
FT   MUTAGEN         1026
FT                   /note="S->A: Prevents phosphorylation by PKA. Loss of
FT                   regulation by cAMP of the transporter stoichiometry."
FT                   /evidence="ECO:0000269|PubMed:11744745,
FT                   ECO:0000269|PubMed:12730338"
FT   MUTAGEN         1026
FT                   /note="S->D: Loss of regulation by cAMP of the transporter
FT                   stoichiometry. Shifts transporter stoichiometry from 3:1 to
FT                   2:1."
FT                   /evidence="ECO:0000269|PubMed:11744745,
FT                   ECO:0000269|PubMed:12730338"
FT   MUTAGEN         1030..1033
FT                   /note="DNDD->NNNN: Abolishes interaction with CA2."
FT                   /evidence="ECO:0000269|PubMed:15218065"
FT   MUTAGEN         1030
FT                   /note="D->N: Loss of regulation by cAMP of the transporter
FT                   stoichiometry. Abolishes interaction with CA2."
FT                   /evidence="ECO:0000269|PubMed:12411514"
FT   MUTAGEN         1032
FT                   /note="D->N: Loss of regulation by cAMP of the transporter
FT                   stoichiometry. Partial loss of interaction with CA2."
FT                   /evidence="ECO:0000269|PubMed:12411514"
FT   MUTAGEN         1033
FT                   /note="D->N: No effect on regulation by cAMP of the
FT                   transporter stoichiometry. Partial loss of interaction with
FT                   CA2."
FT                   /evidence="ECO:0000269|PubMed:12411514"
FT   MUTAGEN         1057
FT                   /note="F->A: Targeting to apical membrane."
FT                   /evidence="ECO:0000269|PubMed:15273250"
FT   CONFLICT        6
FT                   /note="V -> A (in Ref. 4; AAG47773)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        49
FT                   /note="T -> A (in Ref. 6; BAH58226)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        78
FT                   /note="S -> G (in Ref. 3; AAF21718)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        256
FT                   /note="S -> F (in Ref. 3; AAD42020)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        263
FT                   /note="D -> E (in Ref. 3; AAF21718)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        298
FT                   /note="P -> H (in Ref. 6; BAH58226)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        364
FT                   /note="H -> R (in Ref. 3; AAF21719)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        605
FT                   /note="I -> V (in Ref. 3; AAF21718)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        654
FT                   /note="S -> P (in Ref. 3; AAF21718)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        749
FT                   /note="D -> G (in Ref. 3; AAF21719)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        799
FT                   /note="Q -> R (in Ref. 4; AAG47773)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        856
FT                   /note="K -> R (in Ref. 4; AAG47773)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        912
FT                   /note="M -> R (in Ref. 3; AAF21718)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        913
FT                   /note="G -> R (in Ref. 3; AAF21719)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        940
FT                   /note="I -> V (in Ref. 3; AAF21718)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1007
FT                   /note="P -> S (in Ref. 3; AAF21719)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1069
FT                   /note="S -> P (in Ref. 3; AAF21719)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   1079 AA;  121461 MW;  14B981A94DD64293 CRC64;
     MEDEAVLDRG ASFLKHVCDE EEVEGHHTIY IGVHVPKSYR RRRRHKRKTG HKEKKEKERI
     SENYSDKSDI ENADESSSSI LKPLISPAAE RIRFILGEED DSPAPPQLFT ELDELLAVDG
     QEMEWKETAR WIKFEEKVEQ GGERWSKPHV ATLSLHSLFE LRTCMEKGSI MLDREASSLP
     QLVEMIVDHQ IETGLLKPEL KDKVTYTLLR KHRHQTKKSN LRSLADIGKT VSSASRMFTN
     PDNGSPAMTH RNLTSSSLND ISDKPEKDQL KNKFMKKLPR DAEASNVLVG EVDFLDTPFI
     AFVRLQQAVM LGALTEVPVP TRFLFILLGP KGKAKSYHEI GRAIATLMSD EVFHDIAYKA
     KDRHDLIAGI DEFLDEVIVL PPGEWDPAIR IEPPKSLPSS DKRKNMYSGG ENVQMNGDTP
     HDGGHGGGGH GDCEELQRTG RFCGGLIKDI KRKAPFFASD FYDALNIQAL SAILFIYLAT
     VTNAITFGGL LGDATDNMQG VLESFLGTAV SGAIFCLFAG QPLTILSSTG PVLVFERLLF
     NFSKDNNFDY LEFRLWIGLW SAFLCLILVA TDASFLVQYF TRFTEEGFSS LISFIFIYDA
     FKKMIKLADY YPINSNFKVG YNTLFSCTCV PPDPANISIS NDTTLAPEYL PTMSSTDMYH
     NTTFDWAFLS KKECSKYGGN LVGNNCNFVP DITLMSFILF LGTYTSSMAL KKFKTSPYFP
     TTARKLISDF AIILSILIFC VIDALVGVDT PKLIVPSEFK PTSPNRGWFV PPFGENPWWV
     CLAAAIPALL VTILIFMDQQ ITAVIVNRKE HKLKKGAGYH LDLFWVAILM VICSLMALPW
     YVAATVISIA HIDSLKMETE TSAPGEQPKF LGVREQRVTG TLVFILTGLS VFMAPILKFI
     PMPVLYGVFL YMGVASLNGV QFMDRLKLLL MPLKHQPDFI YLRHVPLRRV HLFTFLQVLC
     LALLWILKST VAAIIFPVMI LALVAVRKGM DYLFSQHDLS FLDDVIPEKD KKKKEDEKKK
     KKKKGSLDSD NDDSDCPYSE KVPSIKIPMD IMEQQPFLSD SKPSDRERSP TFLERHTSC
//
